Penicillin-binding proteins Inhibitors
1 drugsAbout Penicillin-binding proteins
Penicillin-binding proteins (PBPs) are bacterial enzymes essential for cell wall biosynthesis, catalyzing the transpeptidation reaction that cross-links peptidoglycans. This provides structural rigidity to the bacterial cell wall, making PBPs critical for bacterial survival.
PBPs are a cornerstone target for antibacterial drug development; inhibiting PBP function disrupts cell wall integrity, leading to bacterial cell death. There is currently no genetic evidence linking PBPs to specific diseases.
PBPs are targeted by one FDA-approved drug, TALICIA, a small molecule used to combat infectious diseases. TALICIA HOLDINGS is the sole company with an approved drug targeting PBPs.
Top Penicillin-binding proteins Drugs
TALICIA HOLDINGS is the only company with an approved drug targeting PBPs.
The lack of competition suggests high barriers to entry or an underserved market, meriting further investigation.
Penicillin-binding proteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Penicillin-binding proteins, using small molecule modality.
Explore opportunities to develop novel PBP-targeting drugs using alternative modalities like antibodies or peptides.
Penicillin-binding proteins Clinical Trials 476 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Penicillin-binding proteins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 150 | 134 | 4 | 12 | 97% |
| Phase 2 | 52 | 29 | 6 | 17 | 83% |
| Phase 3 | 88 | 56 | 12 | 20 | 82% |
| Phase 4 | 186 | 120 | 21 | 45 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Penicillin-binding proteins Drug Approval Timeline (2019 - 2019)
The first and most recent drug approval for a PBP target was TALICIA in 2019.
The recent approval and lack of subsequent drugs suggests a potential for growth in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 300 (89 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Penicillin-binding proteins. A trial counts if an approved drug acting on Penicillin-binding proteins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.